Further improvement in glycemic control after switching from exenatide two times per day to exenatide once-weekly autoinjected suspension in patients with type 2 diabetes: 52-week...

by Carol H Wysham, Julio Rosenstock, Marion L Vetter, Elise Hardy, Nayyar Iqbal
Published 2020-04-01

Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors

by Carol H. Wysham, Patrick Lefebvre, Dominic Pilon, Mike Ingham, Marie-Hélène Lafeuille, Bruno Emond, Rhiannon Kamstra, Wing Chow, Michael Pfeifer, Mei Sheng Duh
Published 2017-06-01

Development of predictive risk models for major adverse cardiovascular events among patients with type 2 diabetes mellitus using health insurance claims data

by James B. Young, Marjolaine Gauthier-Loiselle, Robert A. Bailey, Ameur M. Manceur, Patrick Lefebvre, Morris Greenberg, Marie-Hélène Lafeuille, Mei Sheng Duh, Brahim Bookhart, Carol H. Wysham
Published 2018-08-01